5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) for acneform rash induced by erlotinib: A case report.
In: Photodiagnosis and photodynamic therapy, Jg. 39 (2022-09-01), S. 102994
report
Zugriff:
Erlotinib is an anticancer drug approved for the treatment of non-small cell lung cancer. It inhibits growth and proliferation of tumor cells by targeting epidermal growth factor receptor (EGFR). Dermatological toxicities are common side effects associated with EGFR inhibition. Here we describe a patient with acneform rash following oral medication of erlotinib, presented as facial erythema, papules and pustules. Two sessions of 5-aminolevulinic acid induced photodynamic therapy (ALA-PDT) with a 2-week interval were performed. No significant side effects or scarring were observed. The patient showed no recurrence within 6 months. Thus, we conclude that ALA-PDT is an effective treatment for skin lesions induced by erlotinib, especially for patients with need to sustain medication.
Competing Interests: Declaration of Competing Interest The authors declare that there is no conflict of interest.
(Copyright © 2022. Published by Elsevier B.V.)
Titel: |
5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) for acneform rash induced by erlotinib: A case report.
|
---|---|
Autor/in / Beteiligte Person: | Yu, Y ; Li, J ; Zou, Y ; Yin, R |
Zeitschrift: | Photodiagnosis and photodynamic therapy, Jg. 39 (2022-09-01), S. 102994 |
Veröffentlichung: | Amsterdam ; Boston : Elsevier, c2004-, 2022 |
Medientyp: | report |
ISSN: | 1873-1597 (electronic) |
DOI: | 10.1016/j.pdpdt.2022.102994 |
Schlagwort: |
|
Sonstiges: |
|